A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93019D00031-0-759302300004-1
Grant search
Key facts
Disease
N/A
Start & end year
20232025Known Financial Commitments (USD)
$3,096,871Funder
National Institutes of Health (NIH)Principal Investigator
ASSOCIATE PROFESSOR Anna DurbinResearch Location
United States of AmericaLead Research Institution
JOHNS HOPKINS UNIVERSITYResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 2 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
To support a phase two clinical trial to evaluate a dengue vaccine candidate.